EPO-like peptide (Sanofi/University of Heidelberg)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameEPO-like peptide (Sanofi/University of Heidelberg)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionHLA-DR antigens-associated invariant chain inhibitorsErythropoietin receptor agonists
TargetsHLA-DR antigens-associated invariant chainErythropoietin receptor
Therapy Area/IndicationsNerve DegenerationRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of HeidelbergSanofi
Active IndicationsN/A
Inactive IndicationsNerve DegenerationRetinal Diseases

Other Information

ATC CodeN/A
Related LinksN/A